Categorized | Journal Articles

Melanoma Journal Articles for February 2017

BMJ Case Reports 2017; doi:10.1136/bcr-2016-218308

CASE REPORT

Risk of cumulative toxicity after complete melanoma response with pembrolizumab

Amy Hsin-Chieh Hsieh1Sarah Faithfull2Michael P Brown1

  • Accepted 20 January 2017
  • Published 1 February 2017

A Melanoma Lymph Node Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: A Second Case of Leucocyte-Tumor Cell Hybridization in Cancer Metastasis

Greggory S. LaBerge , Eric Duvall, Zachary Grasmick, Kay Haedicke, John Pawelek

 

 


Ophthalmic Images

February 9, 2017

Regression of Iris Metastasis After Systemic Treatment With Melanoma-Targeted Therapy

Cristina Fonseca, MD, MSc1Júlia Fernandes, MD1Rui Proença, MD, PhD1

Author Affiliations

JAMA Ophthalmol. 2017;135(2):e165462. doi:10.1001/jamaophthalmol.2016.5462


AIM2 absent in melanoma 2 [ Mandrillus leucophaeus (drill) ]

Gene ID: 105538735, updated on 8-Feb-2017


https://www.ncbi.nlm.nih.gov/gene/105538735


Comprehensive measurement of UVB-induced non-melanoma skin cancer burden in mice using photographic images as a substitute for the caliper method

Marc Bazin, Nupur K. Purohit, Girish M. Shah

 

 

Published: February 10, 2017

http://dx.doi.org/10.1371/journal.pone.0171875


Dove Press

First-line treatment of metastatic melanoma: role of nivolumab

Authors Force J, Salama AK

Received 13 April 2016

Accepted for publication 27 July 2016

Published 13 February 2017 Volume 2017:6 Pages 1—10

DOI https://doi.org/10.2147/ITT.S110479


Clinical Cancer Research

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: a Phase 1 Clinical Trial

Mark A Exley, Philip Friedlander, Nadia Alatrakchi, Lianne Vriend, Simon C Yue, Tetsuro Sasada, Wanyong Zang, Yo Mizukami, Justice Clark, David Nemer, Ken LeClair,Christine Canning, Heather Daley, Glenn Dranoff, Anita Giobbie-Hurder, F. Stephen Hodi, Jerome Ritz and Steven P. Balk

DOI: 10.1158/1078-0432.CCR-16-0600 Published 13 February 2017


Oncology Letters

Zerumbone inhibits melanoma cell proliferation and migration by altering mitochondrial functions

Authors: Hua Yan, Ming?Yuan Ren, Zheng?Xiang Wang, Shi?Jun Feng, Si Li, Yi Cheng, Cai?Xia Hu, Shun?Qiang Gao, Guo?Qiang Zhang

Published online on: Tuesday, February 14, 2017

DOI: 10.3892/ol.2017.5742


© 2017

Melanoma Development

Molecular Biology, Genetics and Clinical Application

Editors: Bosserhoff, Anja (Ed.)

  • ISBN 978-3-319-41319-8

Melanoma Development 2nd Edition

 

 

 

 

 

 

 

 


Cancer Biology & Therapy

Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone

Kristian M. KollerHeath B. MackleyJason LiuHenry WagnerGiampaolo TalamoTodd D. Schell show all

Pages 36-42 | Received 10 Oct 2016, Accepted 20 Nov 2016, Accepted author version posted online: 01 Dec 2016, Published online: 01 Dec 2016

http://dx.doi.org/10.1080/15384047.2016.126454


Journal of Cancer Science & Therapy

Received date: November 16, 2016; Accepted date: January 25, 2017; Published date: January 27, 2017

Citation: Frankel AE, Frenkel EP (2017) Melanoma Metamorphoses:Advances in Biology and Therapy. J Cancer Sci Ther 9: 325-335. doi:10.4172/1948-5956.1000437


BioRixv

Stochastic model of contact inhibition and the proliferation of melanoma in situ

Mauro Cesar C Morais, Izabella Stuhl, Alan U Sabino, Willian W Lautenschlager, Alexandre S Queiroga,Tharcisio C Tortelli, Roger Chammas, Yuri Suhov, Alexandre F Ramos

doi: https://doi.org/10.1101/110007


Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab

Yana G. Najjar, Fei Ding, Yan Lin, Robert VanderWeele, Lisa H. Butterfield and Ahmad A. Tarhini

Journal of Translational Medicine 2017 15:39

DOI: 10.1186/s12967-017-1140-9

 

Received: 23 November 2016

Accepted: 4 February 2017

Published: 21 February 2017


IRE1 -XBP1 pathway promotes melanoma progression by regulating IL-6/STAT3 signaling

Cheng Chen and Xuejun Zhang

Journal of Translational Medicine 2017 15:42

DOI: 10.1186/s12967-017-1147-2

 

Received: 6 November 2016

Accepted: 4 February 2017

Published: 21 February 2017


Characterization of long noncoding RNA and messenger RNA signatures in melanoma tumorigenesis and metastasis

Siqi Wang, Wenliang Fan, Bing Wan, Mengqi Tu, Feng Jin, Fang Liu, Haibo Xu, Ping Han

 

 


Journal of Clinical Oncology

Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma

Christine G. KohnSimon B. ZeichnerQiushi ChenAlberto J. MonteroDaniel A. Goldstein, and Christopher R. Flowers
DOI: http://dx.doi.org/10.1200/JCO.2016.69.6336


­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

American Journal of Clinical Dermatology

Next-Generation Sequencing to Guide Treatment of Advanced Melanoma

Klaus G. Griewank, Bastian Schilling

Current Opinion

First Online: 22 February 2017

DOI: 10.1007/s40257-017-0260-6


Photoacoustic imaging features of intraocular tumors: Retinoblastoma and uveal melanoma

Guan Xu, Yafang Xue, Zeynep Gürsel Özkurt, Naziha Slimani, Zizhong Hu, Xueding Wang, Kewen Xia, Teng Ma, Qifa Zhou, Hakan Demirci

 

 


Clinical Cancer Research

Biology of Human Tumors

Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho

Reeti Behera, Amanpreet Kaur, Marie R Webster, Suyeon Kim, Abibatou Ndoye, Curtis H Kugel, Gretchen M. Alicea, Joshua X Wang, Kanad Ghosh, Phil F Cheng, Sofia Lisanti, Katie Marchbank, Vanessa Dang, Mitchell Paul Levesque, Reinhard Dummer, Xiaowei Xu, Meenhard Heryn, Andrew E. Aplin, Alexander Roesch, M. Cecilia Caino, Dario C. Altieri and Ashani T Weeraratna

DOI: 10.1158/1078-0432.CCR-17-0201 Published 23 February 2017


Future Medicine

Immunotherapy

March 2017 ,Vol. 9, No. 3, Pages 225-228 , DOI 10.2217/imt-2016-0136

(doi:10.2217/imt-2016-0136)

 

Case report

A rapid response to pembrolizumab in a patient with metastatic melanoma

Juan Bayo Calero*, & Victoria Aviñó Tarazona


Cancer Immunology, Immunotherapy

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors

Reinhard Dummer, Christoph Hoeller, Isabella Pezzani Gruter, Olivier Michielin

First Online: 25 February 2017

DOI: 10.1007/s00262-017-1967-1


Oncotarget

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p

Valentina Audrito1,2,*, Sara Serra1,2,*, Aureliano Stingi1,2, Francesca Orso3, Federica Gaudino1,2, Cinzia Bologna1,2, Francesco Neri1, Giulia Garaffo3, Romina Nassini4, Gianna Baroni5, Eliana Rulli6, Daniela Massi5, Salvatore Oliviero1,7, Roberto Piva3, Daniela Taverna3, Mario Mandalà8,**, Silvia Deaglio

DOI: 10.18632/oncotarget.15213

Received: August 11, 2016    Accepted: January 06, 2017    Published: February 09, 2017


 

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories